When does Korlym (mifepristone) patent protection run out?
Korlym (mifepristone) patent-expiration timing depends on which specific patent family is being referenced. The information provided here does not include the relevant Korlym patent list, jurisdiction (for example, U.S. vs. EU), or dates for each patent, so the exact “patent runs out” date can’t be determined from the material available.
What date should people actually look for: patent expiry vs. market exclusivity?
Even when a patent expires, drug marketing may still be protected by other legal exclusivities (which can vary by country). That’s why the commonly searched dates are:
- the end date of the last relevant patent (or patents covering specific claims or formulations), and
- the end date of any regulatory market exclusivity terms (which can extend beyond patent expiry in some jurisdictions).
Which country’s answer do you need?
Patent calendars differ by jurisdiction. If you tell me whether you mean the U.S., the EU/UK, or another country—and ideally the exact question you mean (last patent, specific patent number, or market exclusivity)—I can narrow down the relevant expiry date(s).
Quick clarification to get you the exact date
Reply with one of the following and I’ll target the right expiry:
- “U.S. last patent on Korlym”
- “EU last patent on Korlym”
- “Market exclusivity end date”
- “Which exact patent number?”
Sources
No sources were provided in the prompt, so I’m unable to cite Korlym patent-expiration dates.